Liminal BioSciences Inc. Common Shares
LMNL
LMNL was delisted on the 25th of September, 2023.
17 hedge funds and large institutions have $934K invested in Liminal BioSciences Inc. Common Shares in 2021 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 1 closing their positions.
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
155% more call options, than puts
Call options by funds: $520K | Put options by funds: $204K
80% more capital invested
Capital invested by funds: $520K → $934K (+$415K)
55% more funds holding
Funds holding: 11 → 17 (+6)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$210K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$194K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$62.3K |
| 4 |
Morgan Stanley
New York
|
+$55.9K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$42.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$51.4K |
| 2 |
VF
Virtu Financial
New York
|
-$39.7K |
| 3 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$13.8K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$8.45K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$1K |
LMNL Hedge Fund Activity: Q2 2021 in Review
17 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Liminal BioSciences Inc. Common Shares (LMNL) for Q2 2021, worth a combined $934K — up 80% from $520K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new LMNL positions and 1 closed out — a net gain of 6 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $210K. The largest seller was Susquehanna Fundamental Investments, cutting an estimated $51.4K.
- 17 institutional investors held Liminal BioSciences Inc. Common Shares (LMNL) as of Q2 2021, up from 11 in Q1 2021.
- Funds reported $934K of Liminal BioSciences Inc. Common Shares stock for Q2 2021, up 80% quarter-over-quarter.
- 7 funds opened new Liminal BioSciences Inc. Common Shares positions in Q2 2021 and 1 closed out, a net change of +6 holders.
- The largest Liminal BioSciences Inc. Common Shares buyer in Q2 2021 was Citadel Advisors, an estimated $210K added.
- The largest Liminal BioSciences Inc. Common Shares seller in Q2 2021 was Susquehanna Fundamental Investments, an estimated $51.4K sold.
Based on aggregated 13F filings for Q2 2021.